Document 2287
 DOCN  M94A2287
 TI    Acceptability of HIV vaccine trials in high risk cohorts in Mombasa,
       Kenya.
 DT    9412
 AU    Bwayo J; Jackson D; Rakwar J; Nyange P; Martin H; Kreiss J; Department
       of Medical Microbiology, University of Nairobi, Kenya.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):339 (abstract no. PC0291). Unique
       Identifier : AIDSLINE ICA10/94370288
 AB    OBJECTIVE: To assess the acceptability of phase III trials of candidate
       HIV vaccines in high risk male and female prospective cohorts in
       Mombasa. METHODS: A standardised questionnaire was administered to a
       sample of HIV seronegative male (m) trucking company employees (n = 67)
       and female (f) sex workers (n = 61) who were enrolled in existing HIV
       high risk cohort studies, as part of the Preparation for AIDS Vaccine
       Evaluation initiative. RESULTS: General knowledge about vaccines was
       tested, with 78% (75%f, 81%m) giving a correct definition of a vaccine,
       91% (88%f, 93%m) able to name a vaccine preventable disease, 48% (48%f,
       49%m) knowing that vaccines are not 100% efficacious, and 34% (33%f,
       36%m) aware that vaccines could have side effects. While 93% (90%f,
       96%m) thought that HIV was a major problem in Kenya, 12% (15%f, 9%m)
       felt at no personal risk of HIV infection. If offered a safe,
       efficacious HIV vaccine, 89% (89%f, 90%m) stated that they would accept.
       If offered participation in a randomized trial of a candidate HIV
       vaccine of unknown efficacy, 84% (87%f, 81%m) agreed to a double blind
       placebo controlled design, 80% (77%f, 82%m) agreed to participate even
       if the vaccine gave them a false positive HIV serologic result, and 84%
       (87%f, 81%m) agreed to a follow up period of 3 to 5 years. Two
       respondants (1f, 1m) said they would increase their number of sex
       partners if in a vaccine trial and 12% (3%f, 19%m) stated that they
       would decrease condom use. This gender difference in anticipated change
       in condom use was the only such difference which was statistically
       significant (p = 0.01). At the end of the questionnaire, 84% (85%f,
       82%m) said they would participate in an HIV vaccine trial, as outlined.
       DISCUSSION: These results suggest that acceptance of an HIV vaccine
       trial would be high in these cohorts. That 19% of men stated that they
       would decrease condom use if in an HIV vaccine trial highlights the need
       for continuing education.
 DE    Adult  Clinical Trials, Phase III/*STATISTICS & NUMER DATA  Cohort
       Studies  Condoms  *Developing Countries  Feasibility Studies  Female
       Human  HIV Infections/EPIDEMIOLOGY/*PREVENTION & CONTROL/TRANSMISSION
       Kenya/EPIDEMIOLOGY  Knowledge, Attitudes, Practice  Male  *Patient
       Acceptance of Health Care  Prospective Studies  Risk Factors  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).